CNS Market Main Competitors
The four main competitors in the global CNS (central nervous system) disease treatment market based on majority share are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., and Novartis AG. They are active in the development of treatments for CNS diseases and have treatments such as somatrogon, fingolimod, Laquinimod, Aducanumab (Aβ mAb), and rivipansel in the pipeline for treatment of different CNS diseases.
THE CNS THERAPEUTICS MARKET
The therapeutic market for CNS disease treatment has a compound annual growth rate of 5.9% and will reach $128.9 billion by the year 2025. The market growth is driven by a rise in the prevalence of mental diseases and the increasing awareness of psychiatric disorders. The major players in the industry based on majority share are Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG. Pfizer has a rare disease team that focuses on develop effective therapies for the patients affected by rare disorders. The Orphan Drug Act of 1983 defined the rare disorders as diseases affecting less than 200,000 people in the United States.
The market size for the treatment of Parkinson's disease was $4.24 billion in the year 2017 and will reach $5.69 billion by 2022 due to its compound annual growth rate of 6.1%. Pfizer Inc. and Teva Pharmaceutical Industries Limited are global competitors in the treatment of overactive bladder whose market will grow at a compound annual growth rate of 2.9% to reach $4.19 billion by the year 2022.
PFIZER INC.
The treatments in their pipeline for the treatment of CNS diseases include tafamidis meglumine, rivipansel, somatrogon, and domagrozumab. Tafamidis meglumine is transthyretin (TTR) dissociation inhibitor and is in the registration stage. Rivipansel is a pan-selectin antagonist and is in phase 3 of testing while somatrogon is a human growth hormone agonist and is in the third phase of testing. Domagrozumab is a myostatin inhibitor and is in the second phase of testing. Pfizer is also developing dopamine 1 activator, which is in the second phase, for the treatment of Parkinson's disease.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
The company is focusing on a pipeline of novel treatments and new drugs aimed at treating CNS conditions. Azilect is in the registration stage for the treatment of Parkison's disease, and Austedo is in the third phase of testing for the treatment of Tourette syndrome. Other treatments in the second phase of testing for the treatment of Huntington disease are Pridopidine and Laquinimod. Laquinimod will also help in the treatment of multiple sclerosis.
BIOGEN INC.
The company has various treatments in development for the treatment of CNS diseases. The treatments in the pipeline for the treatment of Alzheimer's disease include Aducanumab (Aβ mAb), E2609 (BACE1 inhibitor), BAN2401 (Aβ mAb), BIIB076, and BIIB092. Aducanumab (Aβ mAb) and E2609 are in the third stage of development, BAN2401 (Aβ mAb) is in the second phase, while BIIB076, and BIIB092 are in the first phase of development. The company also has BIIB054 (anti-α-synuclein) in the first phase of development for the treatment of Parkinson's disease. BIIB098 (monomethyl fumarate prodrug) is in the third phase of testing and Opicinumab (anti-LINGO) is in the second phase of testing for the treatment of multiple sclerosis.
NOVARTIS AG.
The treatments in the pipeline for the treatment of Alzheimer's disease are amilomotide and CNP520, and they are both in the second phase of development. A treatment known as fingolimod is also in the registration phase and will be used for the treatment of pediatric multiple sclerosis. Norvatis is also developing a treatment known as Nilotinib (Tasigna®), which was successful in the first phase of treatment of Parkinson's disease but is yet to proceed to the second phase because of disagreements on how to run it.
CONCLUSION
In conclusion, the four major competitors in the CNS (central nervous system) disease treatment market globally based on majority share are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., and Novartis AG. The companies also have various treatments such as rivipansel, somatrogon, fingolimod, Aducanumab (Aβ mAb), and Laquinimod in the pipeline for the treatment of different CNS diseases.